Mayo Clinic Multiple Myeloma SPORE

梅奥诊所多发性骨髓瘤孢子

• 批准号: 10488637
• 负责人: Peter Leif Bergsagel
• 金额: $ 203.16万
• 依托单位: MAYO CLINIC ARIZONA
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10488637
• 关键词: Address; Advocate; Area; Arizona; Basic Science; Benign; Bioinformatics; Biological Specimen database; Biology; Biometry; Bispecific Antibodies; Cancer Center; Cancer Research Project; Caring; Clinic; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Complement; Comprehensive Cancer Center; Development; Early Diagnosis; Florida; Foundations; Functional disorder; Funding; Genetic; Goals; Immune response; Immunotherapy; Infrastructure; Institution; Integration Host Factors; International; Joints; Laboratories; Leadership; Malignant - descriptor; Minnesota; Multiple Myeloma; Ontario; Patients; Peer Review; Peer Review Grants; Phase I Clinical Trials; Prevention; Prognosis; Publications; Regimen; Research; Research Personnel; Research Project Grants; Research Support; Resources; Risk; Site; Translating; Tumor Biology; Tumor Markers; Vesicular stomatitis Indiana virus; Virotherapy; Work; base; career; clinical database; clinical epidemiology; high risk; improved; innovation; multiple omics; novel; oncolytic virotherapy; prognostic index; programs; sound; success; survivorship; translational cancer research; translational clinical trial; translational scientist; treatment optimization; tumor microenvironment; tumor-immune system interactions

PROJECT SUMMARY/ABSTRACT The Mayo Clinic Multiple Myeloma SPORE (SPORE) is a dynamic, productive, translational cancer research program based at all three Mayo Clinic sites (Rochester MN, Jacksonville FL, Phoenix AZ), now with input from the Princess Margaret Cancer Centre in Toronto, Ontario. From 2003-2013 we participated in the joint DFCI/Mayo Clinic Multiple Myeloma SPORE, and since 2015 in the Mayo Clinic Multiple Myeloma SPORE. At the center of the ongoing success of the SPORE is the collaborative interaction between investigators throughout the Mayo Foundation, as well as SPORE basic laboratory, translational and clinical investigators and patient advocates focused on MM. The overall goal of the SPORE is to support innovative, interactive, rigorous translational myeloma research that leverages the expertise of laboratory, translational and clinical expertise. Over the last funding period, the SPORE has been highly productive as demonstrated by identification of new tumor markers and prognostic indices that are being used clinically; scientific findings that led to innovative clinical trials both within and outside the SPORE; multiple publications with many authored by investigators from multiple sites; and brisk accrual to translational clinical trials. The SPORE was involved in multiple productive vertical and horizontal collaborations with other national and international academic institutions and organizations. For example, with leadership of clinical efforts in patient-focused clinical trials from the Multiple Myeloma Research Foundation, International Myeloma Foundation, and MyelomaCrowd. The current proposal includes 3 major research projects. Two of the projects are new, based on research results obtained over the past funding period, while Project 1 is a continuation of efforts to investigate ways of modulating the immune micro-environment to improve the efficacy of oncolytic viral therapy in MM in a phase I clinical trial. Project 2 is an integrated multi-omic analysis of high-risk MM with associated clinical trial highly focused on identifying promising approaches in this group of patients that have not benefited from recent advances. Project 3 is investigating the genetic and microenvironmental mechanisms of progression of smoldering MM to MM to enable early detection of MM requiring treatment. The SPORE also includes Developmental Research and Career Enhancement Programs to pursue novel translational concepts in MM research and new investigators through the programs respectively. Finally, the SPORE will enhance the infrastructure that supports translational MM research through shared core resources in Administration, Biostatistics & Bioinformatics, and Biospecimens & Clinical Database.

项目总结/摘要 马约诊所多发性骨髓瘤孢子（孢子）是一个动态的，富有成效的，转化的癌症研究 该计划基于所有三个马约诊所（罗切斯特明尼苏达州、杰克逊维尔佛罗里达州、凤凰城亚利桑那州），现在输入来自 位于安大略多伦多的玛格丽特公主癌症中心。从2003年到2013年，我们参加了联合 DFCI/马约诊所多发性骨髓瘤孢子，自2015年以来在马约诊所多发性骨髓瘤孢子。在 SPORE持续成功的核心是研究人员之间的协作互动 整个马约基金会，以及SPORE基础实验室，翻译和临床研究人员 SPORE的总体目标是支持创新，互动， 严格的转化骨髓瘤研究，利用实验室，转化和临床的专业知识 专业知识在上一个融资期间，SPORE的生产力很高， 识别临床上使用的新肿瘤标志物和预后指标;科学发现， 在SPORE内部和外部进行了创新性临床试验;发表了多篇出版物，其中许多作者是 来自多个研究中心的研究者;以及快速增加转化临床试验。孢子参与了 与其他国家和国际学术机构的多个富有成效的纵向和横向合作 机构和组织。例如，在以患者为中心的临床试验中， 来自多发性骨髓瘤研究基金会，国际骨髓瘤基金会和骨髓瘤人群。的 目前的建议包括三个主要研究项目。其中两个项目是基于研究成果的新项目 项目1是继续努力，探讨 调节免疫微环境以改善溶瘤病毒疗法在MM中的I期疗效 临床试验项目2是一项针对高危MM的综合多组学分析，相关临床试验高度 专注于在这组患者中确定有希望的方法，这些患者没有从最近的 预付款。项目3正在研究遗传和微环境机制的进展， 将MM阴燃至MM，从而能够早期检测需要治疗的MM。该孢子还包括 发展研究和职业提升计划，以追求MM的新翻译概念 研究和新的研究人员通过方案分别。最后，SPORE将增强 基础设施，支持翻译MM研究，通过共享核心资源在管理， 生物统计学和生物信息学，生物标本和临床数据库。